Clinical Trial

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Study acronym: CANYON-1
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 29, 2026 (before its estimated July 2, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will compare three doses of CRB-913 with placebo to evaluate safety, effects on body weight, and drug levels in the blood. Part 2 is blinded, meaning participants, study doctors, and the sponsor will not know which treatment is given. Participants in Part 2 will take study treatment for 12 weeks and will be followed for 28 days after treatment ends.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-30
Trial Details
NCT Number NCT07310901
Lead Sponsor Corbus Pharmaceuticals Inc.
Conditions Obese But Otherwise Healthy Participants
Enrollment 252 participants
Start Date 2025-12-04
Primary Completion 2026-07-02 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-29